Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of March 2022, with the report issued on March 1, 2022. The filing announces a significant regulatory milestone regarding the company's investigational drug, daprodustat, for the treatment of anaemia of chronic kidney disease (CKD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific regulatory event rather than a financial results announcement.
Material Changes and Regulatory Milestones
- EMA Acceptance: The European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for daprodustat.
- Indication: The application is for the treatment of anaemia of chronic kidney disease (CKD) in adult patients, both on and not on dialysis.
- Global Context: This submission represents the first major regulatory milestone for daprodustat since its approval in Japan in 2020 under the brand name Duvroq.
- Future Filings: GSK anticipates continuing regulatory filings with health authorities worldwide throughout 2022.
Clinical Data and Management Commentary
The MAA is supported by the ASCEND Phase III clinical trial programme, which included five pivotal studies enrolling over 8,000 patients treated for up to 4.26 years. Key findings include:
- Efficacy: Daprodustat improved and/or maintained haemoglobin (Hb) levels within the target range of 10-11.5 g/dL compared to the standard of care (erythropoietin stimulating agents or ESA).
- Safety: The drug demonstrated non-inferiority regarding major adverse cardiovascular events (MACE) in intention-to-treat populations across both non-dialysis (ASCEND-ND) and dialysis (ASCEND-D) settings.
- Publication: Results from the key cardiovascular outcomes studies were published in the New England Journal of Medicine in November 2021.
Risks and Contingencies: GSK includes a cautionary statement noting that forward-looking statements are subject to risks and uncertainties, including those described in the 2020 Annual Report on Form 20-F, Q4 results, and potential impacts of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the timeline for the EMA's final decision on the daprodustat marketing authorisation.
- Confirm the status of regulatory filings in other major markets (e.g., US FDA) anticipated for 2022.
- Review the full ASCEND Phase III trial data published in the New England Journal of Medicine for detailed safety and efficacy profiles.
- Assess the potential commercial impact of daprodustat on GSK's renal portfolio relative to existing ESA therapies.